A Phase 3, Randomized, Placebo-controlled, Double-blind Study of Vimseltinib to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell Tumor (MOTION)
Latest Information Update: 11 Nov 2026
At a glance
- Drugs Vimseltinib (Primary)
- Indications Giant cell tumour of tendon sheath
- Focus Registrational; Therapeutic Use
- Acronyms MOTION
- Sponsors Deciphera Pharmaceuticals
Most Recent Events
- 26 Oct 2026 Results presented in the Merck and co.media release.
- 20 Mar 2026 Planned End Date changed from 1 Jul 2026 to 1 Jul 2028.
- 13 Nov 2025 According to Ono Pharmaceutical media release, data from this study will be presented during the CTOS Annual Meeting 2025, taking place November 12-15 in Boca Raton, Florida.